A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Tufts Medical Center
- Enrollment
- 120
- Locations
- 2
- Primary Endpoint
- Appendicular Lean Mass (ALM)
- Status
- Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
Severe skeletal wasting and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low- or high-dose protein supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothesize that skeletal muscle wasting in HFrEF is promoted by neurohumoral activation of catabolic metabolism (such as GDF-15 and ActRII pathways) and can be at least partially reversed by increased dietary protein intake. It is anticipated that this study will determine whether dietary protein supplementation helps to prevent muscle wasting and will advance understanding of the GDF-15 and ActRII muscle wasting pathways.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association (NHYA) class II to IV symptoms or N-terminal pro B-natriuretic peptide (NT-proBNP) \>300 pg/mL
- •Age 18 years to 100 years, inclusive
- •Receiving guideline-directed medical therapy (GDMT), unless contraindicated or not tolerated
- •Any of the following markers of severe HF within prior 12 months: i) Inotropic therapy; ii) 1 or more HF hospitalizations; iii) LVEF ≤25%; iv) Peak oxygen consumption (VO2) \<50% predicted or ≤16 mL/kg/min; v) 6-minute walk distance \<300 meters; vi) Unintentional weight loss \>5% of bodyweight over the past year; vii) Moderate or severe muscle wasting on physical examination; viii) NT-proBNP ≥900 pg/mL
Exclusion Criteria
- •Pregnancy, planning to become pregnant, or women of reproductive potential unwilling to complete pre-DXA urine pregnancy test before first DXA or randomization
- •History of left ventricular assist device (LVAD), heart transplantation, or estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73 m2
- •An identified clinical disorder associated with skeletal muscle weakness/wasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score greater or equal to 4 post-stroke)
- •Milk allergy, protein allergy, lactose intolerance, and galactosemia
- •Weight ≥350 pounds and/or BMI ≥40 kg/m2
- •Initiation of obesity-dosed GLP-1 or GIP/GLP-1 agonist within 3 months prior to screening, or clinical intention to begin such an anti-obesity medication within the next 6 months.
Outcomes
Primary Outcomes
Appendicular Lean Mass (ALM)
Time Frame: 6 month study visit
ALM as measured by dual X-ray absorptiometry (DXA)
Secondary Outcomes
- Appendicular Lean Mass (ALM)(3 month study visit)
- Protein intake(3 month study visit)
- 6-minute walk test (6MWT)(3 month study visit)
- Handgrip strength(3 month study visit)
- Short physical performance battery (SPPB)(3 months)